Last reviewed · How we verify
NCT04726787: REMIT
RadiothErapy priMIng for CAR-T
NA trial testing Bridging Radiotherapy in Diffuse Large B Cell Lymphoma in 6 participants. Participants enrolled and being followed up; not accepting new ones.
5 July 2023
Quick facts
| Lead sponsor | University College, London |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 18 August 2022 |
| Primary completion | 5 July 2023 |
| Estimated completion | 30 June 2025 |
| Sites | 3 locations across United Kingdom |
Drugs / interventions tested
- Bridging Radiotherapy
Conditions studied
- Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →
Sponsor
University College, London
Who can join
18 and older, any sex, with Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The REMIT trial will investigate radiotherapy as a preferred bridging method prior to Tisagenlecleucel infusion in patients with relapsed or refractory Diffuse Large B Cell Lymphoma
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.
Hovhannisyan L, Riether C, Aebersold DM, Medová M, et al · · 2023 · cited 46× · PMID 37173782 · DOI 10.1186/s12943-023-01775-1 -
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.
Holtermann A, Gislon M, Angele M, Subklewe M, et al · · 2024 · cited 13× · PMID 39080180 · DOI 10.1007/s40259-024-00669-y -
Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.
Freret ME, Tringale KR, Boe L, Imber BS, et al · · 2023 · cited 6× · PMID 37706509 · DOI 10.1080/10428194.2023.2255706 -
[Exploration of CAR-T cell combination therapy strategies in lymphoma].
Zhang YQ, Mei H, Hu Y. · · 2022 · cited 1× · PMID 36709205 · DOI 10.3760/cma.j.issn.0253-2727.2022.10.014 -
MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.
Kuhnl A, Bouziana S, Barrington SF, Galani S, et al · · 2025 · PMID 40936317 · DOI 10.1111/bjh.70137
Verify or expand the search:
- PubMed search for NCT04726787
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diffuse Large B Cell Lymphoma
Currently open trials in the same condition.
- NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
- NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
- NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
- NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting
Other University College, London trials
Trials by the same sponsor.
- NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
- NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
- NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
- NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
- NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04726787 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University College, London
- Last refreshed: 9 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04726787.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing